CompletedNCT01051531
A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia
Researchers studied Paliperidone palmitate to find out how it affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–50Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Paliperidone palmitate to find out how it affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Dandenong, Australia · Elizabeth Vale, Australia and 39 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: April 22, 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 546
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Australia, New Zealand, China, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT01051531
- Official title
Show the full official title
Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics
Recruitment & locations
CompletedDandenong, Australia · Elizabeth Vale, Australia · Epping, Australia
38 more locations
- Frankston, Australia
- Glenside, Australia
- Heidelberg, Australia
- Melbourne, Australia
- Prahran, Australia
- Westmead, Australia
- Beijing, China
- Guangzhou, China
- Nanjing, China
- Shanghai, China
- Xi'an, China
- Hong Kong, Hong Kong
- Johor Bahru, Malaysia
- Kota Bharu, Malaysia
- Kota Kinabalu, Malaysia
- Kuala Lumpur, Malaysia
- Kuching, Malaysia
- Tanjong Rambutan, Malaysia
- Terengganu, Malaysia
- Auckland, New Zealand
- Pasig, Philippines
- Pasig National Capitol Region, Philippines
- Busan, South Korea
- Daegu, South Korea
- Daejeon, South Korea
- Gwangju, South Korea
- Gyeonggi-do, South Korea
- Incheon, South Korea
- Seoul, South Korea
- Changhua County, Taiwan
- Kaohsiung City, Taiwan
- Taichung, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
- Bangkok, Thailand
- Khon Kaen, Thailand
- Songkhla, Thailand
- Ubon Ratchathani, Thailand
Questions about this study
What did researchers investigate?
Researchers studied Paliperidone palmitate to find out how it affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone palmitate.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolarity